Norris Medicines Ltd

Norris Medicines Ltd

Norris Medicines Ltd has submitted a compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30th September, 2026, confirming the dematerialisation of securities and listing on stock exchanges.

Norris Medicines Ltd

Norris Medicines Ltd has announced the voting results and scrutinizer's report for its 35th Annual General Meeting (AGM) held on September 29, 2026. The meeting was conducted through video conferencing, and remote E-voting was offered to shareholders. All resolutions were passed with the requisite majority.

Norris Medicines Ltd

Norris Medicines Ltd has announced the voting results and scrutinizer's report for its 35th Annual General Meeting (AGM) held on September 29, 2026. The company has confirmed that all resolutions were passed with the requisite majority.

Norris Medicines Ltd

Norris Medicines Ltd held its 35th Annual General Meeting (AGM) on September 29th, 2026, through video conferencing. The meeting was attended by 40 members, and the agenda items included the adoption of audited financial statements, appointment of a director, and special resolutions for the appointment of a managing director, increase in borrowing limits, and sale/disposal of the company's undertaking.

Norris Medicines Ltd

Norris Medicines Ltd held its 35th Annual General Meeting (AGM) on September 29th, 2026, through video conferencing. The meeting was attended by 40 members, and the agenda items included the adoption of audited financial statements, appointment of a director, and special resolutions for borrowing limits, sale/disposal of undertaking, and enhancement of existing limits under Section 186 of the Companies Act, 2013.

Norris Medicines Ltd

Norris Medicines Ltd held its 35th Annual General Meeting (AGM) on September 29th, 2026, through video conferencing. The meeting was attended by 40 members, and the agenda items included the adoption of audited financial statements, appointment of a director, and special resolutions for various corporate actions.

Norris Medicines Ltd

Norris Medicines Ltd has announced the closure of its trading window for designated persons, including promoters, directors, auditors, and key managerial personnel, effective from October 1, 2026. The trading window will reopen 48 hours after the declaration of unaudited financial results for the quarter ending September 30, 2026.

Norris Medicines Ltd

Norris Medicines Ltd has announced the outcome of its Board Meeting held on 03rd September, 2026, where the Board approved various matters including the Directors Report, closure of Register of Members, and convening of the 35th Annual General Meeting.

Norris Medicines Ltd

Norris Medicines Ltd has appointed Mr. Vimal Dhirendra Shah as Managing Director (Promoter and Executive) for a term of 3 years effective from September 1, 2026. The appointment is subject to shareholder approval.

Norris Medicines Ltd

Norris Medicines Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, along with the appointment of Mr. Vimal Dhirendra Shah as a Managing Director for a term of 3 years. The company has also disclosed the details required under Regulation 30 of the Listing Regulations.

Norris Medicines Ltd

Norris Medicines Ltd has announced its un-audited financial results for the quarter ended June 30, 2026, along with the appointment of Mr. Vimal Dhirendra Shah as the Managing Director for a term of 3 years, effective from September 1, 2026.

Norris Medicines Ltd

Norris Medicines Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 14/08/2026 to consider and approve Unaudited Financial Results for the quarter ended June 30, 2026.

Norris Medicines Ltd

Norris Medicines Ltd has appointed Mr. Iqubal Ismail Patel as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company, effective July 30, 2026. Mr. Patel has over 11 years of experience in finance, accounts, taxation, budgeting, financial planning, and corporate management.

Norris Medicines Ltd

Norris Medicines Ltd has appointed Mr. Iqubal Ismail Patel as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the company, effective July 30, 2026.